About Tirzepatide Report
An evidence-based, drug-focused guide to tirzepatide.
Edited by Alan Pierce, Clinical Pharmacology Writer. Alan Pierce is Tirzepatide Report's clinical pharmacology writer, covering tirzepatide's mechanism, trials, dosing, and safety. Every claim is tied to primary research or official labeling.
What we publish
The bulk of the site is a clinical corpus: every claim in our research library is tied to a registration trial, a peer-reviewed paper, or the FDA label, and each article carries its own numbered reference list so you can check the source rather than take our word for it.
Alongside it we keep a commercial layer, because the practical question after “does this drug work” is always “where do I get it and what will it cost.” Our ranked provider rankings judge telehealth programs on price transparency, clinical oversight, and support, and the tirzepatide price index publishes the underlying figures — each one carrying the dose it applies at and whether the product is brand or compounded — as a table, a CSV, and a JSON feed. The same reviews also feed a trust & verification index — which LegitScript badges we traced to LegitScript’s own CDN, which FDA warning-letter claims checked out against FDA’s own database, and which providers name their compounding pharmacy.
How a price gets verified, when a stale one is pulled, and how commercial relationships are kept out of the ranking are all set out in our editorial policy.
Contact
Questions, corrections, or editorial feedback are welcome. Reach the Tirzepatide Report team at contact@tirzepatidereport.com.